Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 12/20 | 0.62 |
| ▸ | EGFR | P00533 | 4/20 | 0.54 |
| ▸ | JAK3 | P52333 | 8/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.50 |
| ▸ | CDK7 | P50613 | 1/20 | 0.49 |
| ▸ | CCNH | P51946 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | BLK | P51451 | 1/20 | 0.48 |
| ▸ | BMX | P51813 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17071639 | 0.94 | BTK (0.65) | BTKEGFRJAK3FGFR2CDK7 | |
| SCHEMBL17071463 | 0.91 | BTK (0.56) | BTKEGFRJAK3 | |
| SCHEMBL17071643 | 0.90 | BTK (0.54) | BTKEGFRJAK3CDK7CCNH | |
| SCHEMBL22213202 | 0.88 | BTK (0.59) | BTKEGFRJAK3FGFR2CDK7 | |
| SCHEMBL17071642 | 0.86 | BTK (0.72) | BTKEGFRJAK3FGFR2CDK7 | |
| SCHEMBL17071459 | 0.86 | BTK (0.60) | BTKEGFRJAK3FGFR2CDK7 | |
| SCHEMBL17071647 | 0.85 | BTK (0.58) | BTKEGFRJAK3 | |
| SCHEMBL17071651 | 0.85 | BTK (0.56) | BTKEGFRJAK3CDK7CCNH | |
| SCHEMBL17071472 | 0.84 | BTK (0.73) | BTKEGFRJAK3FGFR2CDK7 | |
| SCHEMBL17062815 | 0.83 | BTK (0.87) | BTKEGFRJAK3JAK2BLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3680238-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | University of Utah Research Foundation (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20180134719-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2018-05-17 | — | — | US | disclosed |
| US-9828376-B2 | Substituted N-(3-pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-11-28 | — | — | US | disclosed |
| US-20150252048-A1 | SUBSTITUTED N-(3-PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | UNIVERSITY OF UTAH | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252048-A1 | SUBSTITUTED N-(3-PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | BTK, SYK, LYN | BTK 1/4885EGFR 294/4885JAK3 41/4885 |
| US-20180134719-A1 | SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS | BTK, SYK, LYN | BTK 1/4885EGFR 323/4885JAK3 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.